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Abstract
Background: Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae are bacteria present in the
nasopharynx as part of normal flora. The ecological equilibrium in the nasopharynx can be disrupted by the presence of
antibiotics.
Methodology/Principal Findings: A computerized two-compartment pharmacodynamic model was used to explore b-
lactam effects on the evolution over time of a bacterial load containing common pharyngeal isolates by simulating free
serum concentrations obtained with amoxicillin (AMX) 875 mg tid, amoxicillin/clavulanic acid (AMC) 875/125 mg tid and
cefditoren (CDN) 400 mg bid regimens over 24 h. Strains and MICs (mg/ml) of AMX, AMC and CDN were: S. pyogenes (0.03,
0.03 and 0.015), S. pneumoniae (2, 2 and 0.25), a b-lactamase positive H. influenzae (BL
+; .16, 2 and 0.06) and a b-lactamase
positive AMC-resistant H. influenzae (BLPACR, .16, 8 and 0.06). Mixture of identical 1:1:1:1 volumes of each bacterial
suspension were prepared yielding an inocula of <4610
6 cfu/ml. Antibiotic concentrations were measured both in bacterial
and in bacteria-free antibiotic simulations. b-lactamase production decreased AMX concentrations and fT.MIC against S.
pneumoniae (from 43.2% to 17.7%) or S. pyogenes (from 99.9% to 24.9%), and eradication was precluded. The presence of
clavulanic acid countered this effect of co-pathogenicity, and S. pyogenes (but not BL
+ and S. pneumoniae) was eradicated.
Resistance of CDN to TEM b-lactamase avoided this co-pathogenicity effect, and CDN eradicated S. pyogenes and H.
influenzae strains (fT.MIC .58%), and reduced in 94% S. pneumoniae counts (fT.MIC <25%).
Conclusions/Significance: Co-pathogenicity seems to be gradual since clavulanic acid countered this effect for strains very
susceptible to AMX as S. pyogenes but not for strains with AMX MIC values in the limit of susceptibility as S. pneumoniae.
There is a potential therapeutic advantage for b-lactamase resistant cephalosporins with high activity against streptococci.
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Introduction
Carriage of common respiratory isolates as Haemophilus
influenzae, Streptococcus pneumoniae and Streptococcus pyogenes depends
on multiple factors such as active or passive smoking, crowding or
age [1], strain fitness properties [2], specific vaccination [3], and
bacterial interference in antibiotic-free niches. H. influenzae and S.
pneumoniae are recovered exclusively from humans and find their
ecological niche in colonizing nasopharynx. Up to 80% of healthy
persons carry H. influenzae [4], with multiple strains in 50% positive
samples [5]. In the case of S. pneumoniae, carriage ranges from 10%
to 40% in an age dependent manner [6], with a lower percentage
of multiple strains in the same sample [7]. While higher turnover
of strains is found in H. influenzae [2], duration of nasopharyngeal
carriage of penicillin-resistant streptococci (PRSP) depends on age,
seasonality, carriage of PRSP by other family members [8], and
serotype, with higher transmission for 6A and 14 [9]. The carriage
of strains resistant to b-lactams is a source of concern in some
countries as Spain where penicillin non-susceptibility in S.
pneumoniae reaches 44% isolates in the community [10], and
ampicillin resistance in H. influenzae attains 25%, with 80% of these
isolates being resistant due to b-lactamase production and 20%
due to the BLNAR (b-lactamase negative ampicillin-resistant)
phenotype [10] caused by mutations in the ftsI gene [11]. Strains
exhibiting both resistant genotypes (TEM- b-lactamase and
mutation in the ftsI gene) constitute the BLPACR (b-lactamase
positive amoxicillin/clavulanate-resistant) phenotype and have
been recently reported as cause of concern [11].
No problems of resistance to b-lactams are found in S. pyogenes,
an ubiquitous microorganism that frequently colonizes throats of
asymptomatic persons, with carriage rates of 15–20% in infants
[12,13] and of 10% in adult smokers [1].
Mucosal surfaces may be simultaneously colonized by multiple
species, and there is an intrincate balance in the oropharynx
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oropharyngeal flora [14]. It has been suggested that this
oropharyngeal flora is altered in S. pyogenes carriers with a decrease
in other streptococcal species (alpha-hemolytic streptococci) with
interfering capabilities [14,15]. On the other side the success of an
organism in colonizing, and maybe in establishing a subsequent
infection, might be determined by its ability to compete with co-
habitants of its niche, since replication/survival of biological
organisms serves to gain space and time [16], and to gain space is
dominance (versus other populations) and to gain time is success
[16]. Dynamics of different bacterial populations in antibiotic-free
niches are the baseline that antibiotic treatments can alter [17,18].
In this study we explored the effect of physiological concentra-
tions of three b-lactams (amoxicillin, amoxicillin plus a b-
lactamase inhibitor, and a third generation oral cephalosporin
resistant to TEM b-lactamases) on the evolution over time of a
bacterial load containing a beta-hemolytic streptococci (S. pyogenes),
an alpha-hemolytic streptococci (a serotype 14 penicillin-resistant
S. pneumoniae), and two b-lactamase positive H. influenzae strains
(one characterized as BLPACR) in the same niche.
Materials and Methods
Strains
Four clinical isolates were used throughout the study: one S.
pyogenes, one serotype 14 penicillin-resistant S. pneumoniae,o n eb-
lactamase TEM-1 producing H. influenzae (BL
+), and one H. influenzae
TEM-1 positive strain presenting a N526K mutation in the ftsIg e n e
(BLPACR). BL
+ was trimethoprim resistant (MIC .128 mg/ml) and
the BLPACR strain was trimethoprim susceptible (0.12 mg/ml); this
difference was used throughout the study to differentiate both strains.
Mutations in the ftsI and TEM-1 genes were determined by PCR
amplification and direct sequencing [19,20].
Culture media and preliminary studies
Different broth media were used in preliminary studies to
determine which media showed the best growth rate over 24 h for
all strains: a) Mueller-Hinton broth (Difco laboratories, Detroit,
Mich.) supplemented with 5% lysed sheep blood (Biomedics,
Madrid, Spain) (MHB) (as media recommended for streptococci)
[21], b) Mueller-Hinton broth supplemented with 15 mg/ml
nicotinamide adenine dinucleotide, 15 mg/ml haemin (Sigma-
Aldrich Chemical Co., St. Louis, USA), and 5 mg/ml of yeast
extract (Difco laboratories) (HTM) (as media recommended for H.
influenzae) [21], c) Todd-Hewitt broth supplemented with 5 mg/ml
of yeast extract, and d) Todd-Hewitt broth (Difco laboratories)
supplemented with 15 mg/ml nicotinamide adenine dinucleotide,
15 mg/ml haemin and 5 mg/ml of yeast extract (THSB). THSB
showed the best growth rate for all strains (data not shown) and
was the selected broth medium for pharmacodynamic simulations.
In vitro susceptibility
MICs of cefditoren, amoxicillin and amoxicillin/clavulanic acid
were determined by the microdilution method following NCCLS/
CLSI recommendations [21], and also using THSB as media
(broth media used in pharmacodynamic simulations). MICs were
determined in triplicate and the modal value of each determina-
tion was considered.
In vitro kinetic model (Figure 1)
Apreviouslydescribedtwo-compartmentdynamicmodelwasused
to expose bacteria to changing study drug concentrations avoiding
the dilution of the bacterial inoculum together with the drug [17,18].
The extra-capillary space and the intra-dialyser circulating tubing of
the second compartment (FX50 helixone dialyzer, Fresenius Medical
Care S.A., Barcelona, Spain), represented the colonisation site. The
central compartment, representing the systemic circulation, consisted
of a spinner flask with THSB, tubing and lumina of capillaries within
a dialyser unit. The exponential decay of concentrationswas obtained
by a continuous dilution-elimination process using computerized
peristalticpumps(Masterflex,Cole-ParmerInstrumentCo.,Chicago,
IL, USA) set to simulate half-lives of amoxicillin, clavulanic acid and
cefditoren. In control drug-free simulations the rate of peristaltic
pumps was fixed to 0.67 ml/min. Additional pumps circulated the
antimicrobial-medium mixture at 50 ml/min rate between the
central and peripheral compartments, and at 25 ml/min within the
extra-capillary space through external tubing. A computer-controlled
syringe pump (402 Dilutor Dispenser; Gilson S.A, Villiers-le-Bel,
France) allowed the simulation of drug concentrations by infusion of
the drug into the central compartment until the maximum
concentration achieved in serum (Cmax) was reached. Both
compartments were maintained at 37uC all over the simulation
process.
Preparation of individual and mixed cultures
The strains were grown overnight on Mueller-Hinton agar
(Difco laboratories) supplemented with 5% lysed sheep blood
(Biomedics) (MHA) in the case of S. pneumoniae and S. pyogenes,o ro n
GC agar (Difco laboratories) supplemented with 5% sheep blood
(added at 50uC) and VX growth factors (GCSA) in the case of H.
influenzae. Several colonies of each strain were suspended in THSB
to obtain a bacterial density of approx. 1610
8 cfu/ml. A 1:100
dilution was prepared to obtain an initial inoculum of approx.
1610
6 cfu/ml. For the mixed inoculum, a mixture of identical
1:1:1:1 volumes of each bacterial suspension was prepared,
yielding an inoculum of approx. 4610
6 cfu/ml.
Experiments
Sixty ml of each individual or of the mixed inoculum were
introduced into the peripheral compartment of the in vitro model
and pre-incubated 1 h. Experiments performed were:
a) Antibiotic-free simulations using each individual inoculum
(individual growth control)
b) Antibiotic-free simulations using the mixed inoculum (mixed
growth control)
c) Bacteria-free simulations with each antibiotic to set the
pharmacokinetic profile of each study drug
d) Simulations with each antibiotic using the mixed inoculum
In each experiment, samples (0.5 ml) from the peripheral
compartment were collected at 0, 2, 4, 6, 8, 10, 12, 24 h. Each
sample was serially ten-fold diluted in 0.9% sodium chloride, and
20 ml plated for bacterial counting onto plates containing different
media to allow species/strains differentiation: a) MHA: growth of
S. pneumoniae and S. pyogenes that were differentiated by their
different hemolytical properties (beta for S. pyogenes and alpha for S.
pneumoniae), b) GCSA: growth of both H. influenzae strains that were
differentiated from the other species by their morphological
properties, c) GCSA containing 4 mg/ml of trimethoprim: growth
of BL
+, not allowing the growth of the BLPACR strain. Colony
counts of the BLPACR strain were calculated by the difference in
colony counts between both GCSA plates. The total population
was established as the accumulated colony counting of S.
pneumoniae and S. pyogenes on MHA and H. influenzae on GCSA
medium. All plates were incubated at 37uC5 %C O 2 for 24 h. The
limit of detection was 50 cfu/ml. All experiments were performed
in triplicate.
b-Lactam Effect on a Carriage
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Free-drug concentrations after oral amoxicillin 875 mg three-times
daily, amoxicillin/clavulanic acid 875/125 mg three-times daily and
cefditoren-pivoxil 400 mg twice daily administration, were simulated
over 24 h using the reported protein binding of 18% for amoxicillin
[22], 25% for clavulanic acid [22], and 88% for cefditoren [23]. The
target total pharmacokinetic parameters were: Cmax=11.6 mg/ml
and t1/2=1.15 h for amoxicillin [22], Cmax=2.20 mg/ml and t1/
2=1.15 h for clavulanic acid [22], and Cmax=4.5 mg/ml and t1/
2=1.55 h for cefditoren [23]. Target free concentrations and
pharmacokinetic parameters are shown in Table 1.
Pharmacokinetic analysis
For the measurement of simulated antimicrobial concentrations,
aliquots (0.5 ml) were taken at 0, 2, 4, 6, 8, 10, 12 and 24 h and at
the time corresponding to Tmax, and stored at 250uC. To study
the influence of bacteria on the pharmacokinetic profile, samples
for measuring antibiotic concentrations were taken both in
bacteria-free antibiotic simulations (carried out to set the model)
and in experimental simulations with bacteria and antibiotic.
Concentrations were determined by bioassay using Morganella
morganii ATCC 8076H as indicator organism for cefditoren [24]
(linear concentrations from 0.0035 to 4 mg/ml; limit of detec-
tion=0.0035 mg/ml), Micrococcus luteus ATCC 9341 for amoxicillin
(linear concentrations from 0.03 to 1 mg/ml; limit of detec-
tion=0.06 mg/ml), and Klebsiella pneumoniae NCTC 11228 for
clavulanic acid concentrations [25] (linear concentrations from
0.06 to 4 mg/ml; limit of detection=0.12 mg/ml). Plates were
inoculated with an even lawn of the indicator organism and
incubated for 18–24 h at 37uC. Intra- and inter-day coefficients of
variation were 2.54% and 2.25% for amoxicillin, 3.68% and
2.02% for clavulanic acid, and 1.97% and 1.97% for cefditoren,
respectively, for an internal control concentration of 0.75 mg/ml.
Antimicrobial concentrations were analysed by a non-compart-
mental approach using WinNonlin 5.2 Professional program
(Pharsight, Mountainview, CA, USA). Cmax and Tmax were
obtained directly from observed data and the area under the
concentration-time curve (AUC) was calculated by the trapezoidal
rule. The percentage of the dosing interval that the unbound
fraction of drug concentrations exceed the MIC, fT.MIC, was
calculated by a non-comportmental approach for pharmacody-
namic data using the model 220 of WinNonlin program.
Measurement of b-lactamase activity
b-lactamase activity was measured in antibiotic simulations with
the mixed inocula at 0, Tmax, 2, 4, 6, 8, 10, 12 and 24 h using a
modification of a previously described method [26,27]. In brief,
0.025 ml of a 500 mg/ml solution of Nitrocefin were added to
225 ml of samples collected at sampling times for colony counting,
and incubated for 30 min at 37uC. Afterwards, 0.75 ml of
phosphate buffer 0.05 M was added and absorbance at 486 nm
(A486) was spectrophotometrically read, using broth without
inoculum as baseline absorbance.
Statistical analysis
Unpaired t test or one-way ANOVA with Tukey post test was
used to compare the concentrations measured and the pharma-
cokinetic parameters calculated in bacteria-free simulations vs.
Figure 1. Pharmacodynamic computerized device. Diagram of the in vitro two-compartment computerized device used in the study.
doi:10.1371/journal.pone.0003846.g001
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lactamase production between simulations with the different study
drugs. A p#0.01 was considered statistically significant.
Results
Pharmacokinetics
Table 1 shows concentrations and pharmacokinetic parameters
experimentally measured in the peripheral compartment in
bacteria-free simulations and in those simulations performed with
the mixed inocula. For cefditoren and clavulanic acid, no significant
differences were found between target free concentrations, those
determined in bacteria-free simulations and those in mixed inocula
simulations. In contrast, for amoxicillin significant differences were
found between concentrations determined in simulations carried
out with the mixed inocula and those measured in bacteria-free
simulations. In amoxicillin simulations (where amoxicillin was not
protected by clavulanic acid) significant lower concentrations of
amoxicillin were found in simulations carried out with the mixed
inocula from Tmax to 8 h (end of the dosing interval), with non-
detectable amoxicillin concentrations from 4 h on. This resulted in
a significant decrease in amoxicillin pharmacokinetic parameters
calculated with amoxicillin concentrations measured in simulations
carried out with the mixed inocula (with its b-lactamase production)
vs. those calculated with concentrations measured in bacteria-free
simulations: Cmax decreased from 9.06 to 5.11 mg/ml, AUC from
20.13 to 5.61 mg/ml6h, and t1/2 from 1.08 to 0.40 h. In
amoxicillin/clavulanic acid simulations, regardless the presence of
clavulanic acid, significant lower concentrations of amoxicillin were
found in simulations carried out with the mixed inocula from 4 to
8 h, although differences in pharmacokinetic parameters were not
significant except for the half-life value (1.16 vs. 0.80 h).
In vitro susceptibility
Table 2 shows in vitro susceptibility (MICs determined following
CLSI recommendations) of study strains to the antibiotics used in
this study. MICs determined in THSB (the broth media used in the
simulations)exhibitedequalvaluestothosedeterminedinthe media
recommended by CLSI, except for the BLPACR strain and
cefditoren, and the BL
+ strain and amoxicillin/clavulanic acid
where MICs in THSB showed one-dilution lower values. S. pyogenes
was susceptible to all antibiotics with MICs #0.03 mg/ml. S.
pneumoniae was susceptible to amoxicillin with or without clavulanic
acid (MIC=2 mg/ml), and although there are not established CLSI
breakpoints for cefditoren, the strain would be classified as
intermediate resistant (MIC=0.25 mg/ml) following the FDA
proposed breakpoints [23]. Both H. influenzae strains were inhibited
by cefditoren concentrations of 0.06 mg/ml, were resistant to
amoxicillin, and the BLPACR strain was also resistant to
amoxicillin/clavulanic acid according to CLSI breakpoints [28].
Pharmacodynamics
Table 2 shows fT.MIC calculated both with concentrations
determined in bacteria-free simulations and in those with the mixed
inocula. Similar values were obtained in both cases for cefditoren
withfT.MIC.55%forH.influenzaeand S.pyogenes,and<25%forS.
pneumoniae. In the case of amoxicillin/clavulanic acid, negligible
values of amoxicillin fT.MIC were obtained against the BLPACR
strain, values for the BL
+ and S. pneumoniae decreased from 40.8% to
32.8% when comparing bacteria-free vs. mixed inocula (with its b-
lactamase production), and were nearly 100% of the dosing interval
for S. pyogenes. Finally, in amoxicillin simulations, where clavulanic
acid was not present to protect amoxicillin, negligible values were
obtained for both b-lactamase producing strains, and fT.MIC
decreased when comparing bacteria-free vs. mixed inocula
simulations from 43.2% to 17.7% (S. pneumoniae) and from 99.9%
to 24.9% (S. pyogenes) in the case of the gram-positive strains.
Fitness in antibiotic-free simulations
Viability in THSB over time in individual and mixed simulations
without antibiotics is shown in Figure 2. In individual cultures mean
colony counts increased from time 0 to 12 and 24 h in $1l o g 10 cfu/
Table 1. Pharmacokinetics.
Cefditoren 400 mg Clavulanic acid 125 mg Amoxicillin 875 mg
AMX simulations AMC simulations
Time (h) Target SBF SMI Target SBF SMI Target SBF SMI SBF SMI
Tmax
a 0.50 0.5260.02 0.5260.03 1.65 1.7060.09 1.4660.11 9.51 9.0560.19 5.1161.27
b 9.1760.24 9.2460.71
2 - 0.3660.00 0.4060.04 1.22 1.1560.13 1.0760.21 7.03 6.3060.51 2.4361.49
b 6.1260.09 6.0460.91
4 0.29 0.2860.04 0.3060.02 0.36 0.2160.03 0.2160.03 2.11 1.7460.00 UDL
b 1.5060.17 0.5960.39
b
6 0.12 0.1260.01 0.1060.03 0.11 0.1360.00 0.1160.00 0.63 0.4560.03 UDL
b 0.4160.05 0.0660.02
b
8 0.04 0.0460.00 0.0560.01 0.03 UDL UDL 0.19 0.1360.03 UDL
b 0.1760.02 0.0460.01
b
10 0.02 0.0260.00 0.0160.01 - - - - - - - -
12 0.01 0.0160.00 0.0160.00 - - - - - - - -
Cmax
c 0.50 0.5260.02 0.5260.03 1.65 1.7060.09 1.4660.10 9.51 9.0660.19 5.1161.27
b 9.1760.24 9.2460.71
AUC
d 1.79 1.7660.05 1.7960.10 3.91 3.2660.09 2.8660.40 22.59 20.1360.52 5.6161.71
b 19.7660.91 15.9061.59
t1/2 (h) 1.55 1.4960.06 1.4860.07 1.15 0.9960.31 1.0360.17 1.15 1.0860.09 0.4060.06
b 1.1660.03 0.8060.03
b
Free concentrations (in beta-phase over the dosing interval) and pharmacokinetic parameters: target values and values determined in bacteria-free simulations (SBF)a n d
in simulations with the mixed inocula (SMI).
aTmax: 2.8 h for cefditoren, 1.5 h for clavulanic acid and amoxicillin.
bp,0.01 versus SBF.
cmg/ml.
dmg6h/L.
UDL=under detection limit.
doi:10.1371/journal.pone.0003846.t001
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found at times 0, 12 and 24 h (<6.05 log10 cfu/ml).
The situation was completely different in simulations with the
mixed inocula. Mean log10 colony counts of the global mixed
inocula were maintained over time (6.55 log10 at time 0, 6.37 log10
at 12 h and 6.10 log10 at 24 h), but the distribution of the bacterial
population highly varied when considering the percentage of cfu/
ml of each strain over 24 h. At time 0 each strain accounted for
approx. 25% of the mixed inocula, and at 24 h up to 96.3% of the
population corresponded to S. pyogenes, with small populations of
the BLPACR strain (3.17%) and S. pneumoniae (0.50%), and colony
counts below the detection limit for the BL
+ strain.
Simulations with antibiotics and mixed inocula
A reduction of 98.5% (<2 log10 cfu/ml) in the initial global
mixed inocula at 24 h was obtained with cefditoren, but no
reductions were obtained with amoxicillin and amoxicillin/
clavulanic acid.
The reduction provided by cefditoren was due to the
disappearance of the S. pyogenes population at 6 h (fT.MIC 79%),
of H. influenzae populations at 12 h (with fT.MIC 58%), and to
94% decrease in the initial S. pneumoniae population at 24 h (with
fT.MIC <25%).
In amoxicillin/clavulanic acid simulations the maintained
counts of BL
+ (fT.MIC 32.8%), and the increase in 0.5 log10 of
the BLPACR population (fT.MIC of only 4.6%) were responsible
for the absence of reduction in the initial global mixed inocula. S.
pneumoniae decreased 0.94 log10 (fT.MIC 32.8%) and S. pyogenes was
not detectable from 10 h on (fT.MIC 99.9%).
In amoxicillin simulations, the maintenance or slight increase in
H.influenzaestrains(fT.MIC0%)producedtheabsence ofreductions
in the initial global mixed inocula at 24 h. S. pneumoniae decreased
only 0.49 log10 and this could be related to the decrease in fT.MIC
from 43.2% in bacteria-free simulations to 17.7% in mixed inocula
simulations due to b-lactamase production and amoxicillin
inactivation as shown in Table 1 (significantly lower amoxicillin
concentrations in mixed inocula vs. bacteria-free simulations). This
inactivation also affected the activity against S. pyogenes, and the
amoxicillin regimen was the only one that was not able to eradicate
this strain (although producing 1.2 log10 reduction), due to the
reduction in fT.MIC from 99.9% to 24.9% when comparing
bacteria-free vs. mixed inocula simulations.
b-lactamase activity
Table 3 shows b-lactamase activity over 24 h in the simulations
carried out with the study drugs. No differences were found
between the three antibiotic regimens until 6 h when differences
between amoxicillin and amoxicillin/clavulanic acid simulations
were significant. At 10 and 12 h significant higher b-lactamase
activity was found in amoxicillin than in amoxicillin/clavulanic
acid simulations, and this could be related with the different
population of the b-lactamase producing strains found in both
simulations at these timepoints: approx. 7.5 log10 in amoxicillin
and approx. 4–5 log10 in amoxicillin/clavulanic acid simulations.
In cefditoren simulations, at 10 h and 12 h, the b-lactamase
activity determined was similar to the one in amoxicillin
simulations. Cefditoren was highly active against the two H.
influenzae strains, and the lysis of these organisms (colony counts
#100 colonies at these timepoints) probably produced release of
the enzyme responsible for the high b-lactamase activity
determined.
At 24 h significantly lower b-lactamase activity (0.05 absor-
bance units) was found in cefditoren simulations (H. influenzae
colony counts below the limit of detection) vs. amoxicillin with or
without clavulanic acid (0.20 absorbance units, a value similar to
time 0) simulations where colony counts were higher than the
initial inocula.
Discussion
Ecology and resistance in human microbiota are related
phenomena since there is some evidence that bacterial fitness
decreases, at least at short term, due to resistance [29]. In
compartment models the fitness of a bacterial strain is directly
proportional to its ability to compete with other strains and
inversely proportional to its clearance [30]. If there is heteroge-
neity in fitness, those strains with higher fitness are anticipated or
eventually prevailed [30]. Dynamics of the different subpopula-
tions in an antibiotic-free environment are the baseline that
antibiotic treatments can alter by interfering with bacterial fitness
(including colonisation and transmission), since resistance can be
associated with a decrease in fitness [31].
In this study we tried to simulate a nasopharyngeal niche by
means of a mixed inocula of common respiratory isolates showing
classical (b-lactamase production in H. influenzae and penicillin
resistance in S. pneumoniae) and emergent but increasing (concom-
itant ftsI gene mutation in the BLPACR strain) resistance
phenotypes. Despite up to 80% of healthy persons carry H.
influenzae [4], with multiple strains in 50% positive samples [5] and
although there is an increasing isolation rate of BLPACR [11], the
use of strains with different resistance phenotypes may be a
limitation of the study. However resistance was needed as a
marker to show differences between the three antibiotics used with
Table 2. Pharmacodynamics.
Cefditoren Amoxicillin Amoxicillin/clavulanic acid
MIC T.MIC MIC T.MIC MIC T.MIC
a
SBF SMI SBF SMI SBF SMI
S. pyogenes 0.015 84.3 79.0 0.03 99.9 24.9 0.03 99.9 99.9
S. pneumoniae 0.25 24.0 25.6 2 43.2 17.7 2 40.8 32.8
H. influenzae BL
+ 0.06 57.4 58.0 .16 0.0 0.0 2 40.8 32.8
H. influenzae BLPACR 0.06 57.4 58.0 .16 0.0 0.0 8 4.5 4.6
In vitro susceptibility (MIC; mg/ml) of the strains used in the study, and T.MIC (% dosing interval) in bacteria-free simulations (SBF) and in simulations with the mixed
inocula (SMI) for bid 400 mg cefditoren, tid 875 mg amoxicillin, and tid 875/125 mg amoxicillin/clavulanic acid regimens.
aon amoxicillin basis.
doi:10.1371/journal.pone.0003846.t002
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resistance) in the presence of b-lactamases. Another limitation of
the study may be the exposition to antibiotics of mixed inocula
with identical proportions of the different strains at time 0. In a
pathological situation, the inoculum of S. pyogenes may be higher
than that of the other microorganisms, as occurred in this study in
antibiotic-free simulations: S. pyogenes was the dominant population
at 24 h (accounting for 96.3%) together with a small population of
b-lactamase producing H. influenzae strain (3.17%). b-lactamase
producing bacteria are frequently found in patients with recurrent
tonsillitis, where the exposure to antibiotics in general and to b-
lactams in particular select them in nasopharyngeal flora [14].
This has lead to the concept of co-pathogenicity (protection of S.
pyogenes susceptible to penicillin by colocalized bacteria resistant to
penicillin due to b-lactamase production) [32–34]. Co-pathoge-
nicity has been hypothesised by some authors to be responsible of
penicillin treatment failures in the treatment of group A b-
hemolytic streptococci pharyngitis due to b-lactamase producing
organisms in the pharynx as H. influenzae or Moraxella catarrhalis
[34], but criticised by others [35,36] on the basis that if there is a
clinical difference (that may be dubious) between penicillin and
cephalosporins, the question of how important is this difference,
Figure 2. Evolution of inocula over time under experimental conditions. Colony counts over 24 h in antibiotic-free individual simulations,
antibiotic-free mixed simulations and in simulations with study drugs (grey: total population, blue: S. pneumoniae, green: S. pyogenes, orange: BL
+,
purple: BLPACR).
doi:10.1371/journal.pone.0003846.g002
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the clinical goal of antimicrobial therapy that should be to
eradicate the infecting pathogen, minimization of resistance
selection in normal nasopharynx flora, and prevention of
transmission of resistant clones from nasopharynx should also be
taken into account.
Pharmacodynamic parameters as serum fT.MIC for b-lactams
can be related to bacterial eradication at the infection site, and the
subsequent therapeutic outcome together with prevention of
resistance [37] also in normal flora. This study explores the effects
of serum drug profiles over 24 h of different b-lactam regimens on
the natural evolution of the simulated niche. Although it may be
argued that serum concentrations do not resemble nasopharynx
concentrations, free-drug concentrations were used as an approx-
imation despite the fact that protein binding of the highly bound
cephalosporin may not highly influence bacterial killing [38]. In
addition, in order to know the effects of b-lactamase production on
antibiotic pharmacokinetics and its consequences on pharmaco-
dynamic parameters predicting antibacterial activity, pharmaco-
kinetic parameters were determined with concentrations measured
in bacterial mixed inocula simulations and in bacteria-free
simulations. The presence of the b-lactamase did not alter the
concentrations of cefditoren (TEM-1 b-lactamase resistant) but
highly modified those of amoxicillin over the entire dosing interval
in amoxicillin tid regimen simulations, and in a lesser extent (from
4 h on) in amoxicillin/clavulanic acid tid regimen simulations.
This led to pharmacokinetic parameters of amoxicillin significantly
lower in mixed inocula simulations, with fT.MIC values different if
b-lactamase activity is considered or not.
As a result, the activity of cefditoren was not influenced by the
presence of b-lactamase, and this cephalosporin eradicated S.
pyogenes and co-pathogens as H. influenzae, and decreased S.
pneumoniae population in 94%. In the case of the tid regimen of
amoxicillin/clavulanic acid, the b-lactamase production by the
BLPACR strain (resistant to amoxicillin/clavulanic acid: fT.MIC
of only 4.6%) protected the BL
+ H. influenzae that although
susceptible to amoxicillin/clavulanic acid (MIC=2 mg/ml;
fT.MIC 32.8%), was not eradicated or even diminished. The
same occurred with S. pneumoniae (MIC=2 mg/ml; fT.MIC 32.8%)
that was only reduced in ,1 log10. However the presence of the b-
lactamase did not avoid eradication of S. pyogenes (MIC=0.03 mg/
ml; fT.MIC 99.9%). On the contrary, in tid amoxicillin
simulations, the maintenance and even increase in b-lactamase
producing strains (fT.MIC 0%) were able to protect not only S.
pneumoniae (because a decrease in fT.MIC from 43.2% to 17.7% in
bacteria-free vs. mixed inocula simulations) but also S. pyogenes
(decrease in fT.MIC from 99.9% to 24.9%) from eradication.
The bacteriological failure rates of penicillins increased from 2
to 10% in the early 70’s, but beginning in the late 70’s, penicillin
bacteriological failure rates increased to 30% in 2000’s [39],
maybe as the prevalence of b-lactamase production increased.
Despite different causes for treatment failure (lack of compliance,
reexposure, eradication of pharyngeal flora, bacterial fitness), and
contradictory reports on the effects of co-pathogenicity [39,40],
the results of this study reinforces the concept of ‘‘indirect
pathogen’’ since b-lactamase production in mixed inocula
(resembling pharyngeal flora) decreased amoxicillin concentrations
and pharmacokinetic parameters against S. pneumoniae or S.
pyogenes, when clavulanic acid was not present, in such a magnitude
that adequate values were not obtained and eradication was
precluded. The presence of clavulanic acid along a tid regimen
countered this effect of indirect pathogenicity by protecting
amoxicillin from b-lactamase degradation, and a very susceptible
strain as S. pyogenes was eradicated. However since the b-lactamase
was produced by a strain resistant to amoxicillin/clavulanic acid
(as the BLPACR strain), clavulanic acid was not able to protect
amoxicillin from degradation in such an extent to allow its
bactericidal activity against strains with MICs in the limit of
susceptibility, as the H. influenzae BL
+ and S. pneumoniae (MICs of
2 mg/ml) that were protected from eradication, thus selecting
them. The quality of TEM b-lactamase resistance of cefditoren
avoided this co-pathogenicity effect of H. influenzae b-lactamase
production.
Although this study is only an approach of what could occur in
the human nasopharynx, the results suggest that, at least in vitro,
the presence of b-lactamase producing microorganisms may
protect other microorganisms present in the niche. This effect of
‘‘indirect pathogen’’ or co-pathogenicity seems to be gradual since
b-lactamase inhibitors (as calvulanic acid in tid regimens)
countered it for strains very susceptible to amoxicillin as S. pyogenes
but not for susceptible strains with amoxicillin MICs values in the
limit of susceptibility as S. pneumoniae. These in vitro findings
indicate a potential therapeutic advantage for b-lactamase
resistant cephalosporins with high intrinsic activity against
streptococci.
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